Showing 1 - 13 results of 13 for search '"Ichihara, Chiba"', query time: 0.13s Refine Results
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8

    Real-World Safety and Effectiveness of Benralizumab in Japanese Patients with Severe Asthma: A Multicenter Prospective Observational Study by Yamaguchi M, Nishimura Y, Takumi Y, Hayashi N, Sakamoto K, Tohda Y

    Published 2024-01-01
    “…Masao Yamaguchi,1 Yoshihiro Nishimura,2 Yuko Takumi,3 Nobuya Hayashi,4 Kei Sakamoto,3 Yuji Tohda5 1Division of Respiratory Medicine, Third Department of Medicine, Teikyo University Chiba Medical Center, Ichihara, Chiba, Japan; 2Kita-Harima Medical Center, Ono, Hyogo, Japan; 3Patient Safety Division, Research and Development, AstraZeneca K.K., Osaka, Japan; 4Data Science and Innovation Division, Research and Development, AstraZeneca K.K., Osaka, Japan; 5Department of Respiratory Medicine and Allergology, Kindai University School of Medicine, Osaka-Sayama, Osaka, JapanCorrespondence: Masao Yamaguchi, Division of Respiratory Medicine, Third Department of Medicine, Teikyo University Chiba Medical Center, Ichihara, Chiba, Japan, Tel +81-436-62-1211, Fax +81-436-62-7340, Email myama@med.teikyo-u.ac.jpIntroduction: This study aimed to demonstrate whether benralizumab maintained the safety and effectiveness profiles established in randomized controlled trials among all patients with severe uncontrolled asthma initially prescribed benralizumab in the real-world setting in Japan.Methods: This was a prospective, observational, multicenter post-marketing study (ClinicalTrial.gov, NCT03588546). …”
    Get full text
    Article
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13